Navigation Links
Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation

Initial Analysis Shows Statistically Significant Changes in Agitation Levels With 10 mg AZ-004

PALO ALTO, Calif., March 26, 2007 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. today announced positive initial results from its Phase IIa clinical trial of AZ-004 (Staccato(R) loxapine) in schizophrenic patients with acute agitation. The 10 mg dose of AZ-004 met the primary endpoint of the clinical trial, which was a statistically-significant reduction in the measure of agitation from baseline to the 2-hour post-dose time point, compared to placebo. Alexza also announced today positive top-line results from its Phase IIb clinical trial of AZ-001 (Staccato prochlorperazine) in patients with migraine headache, where AZ-001 met the primary endpoint of the Phase IIb clinical trial.

"AZ-004 is a product candidate that we believe could fill an important unmet need in the acute treatment of agitation in schizophrenic patients," said Thomas B. King, President and CEO of Alexza. "AZ-004 combines drug delivery speed comparable to that of an intravenous injection, but with the simplicity, convenience and ease of administration of a simple, one-breath inhalation."

"Antipsychotic drugs used to treat acute agitation are typically administered by intramuscular injection, usually in a clinic or in an emergency department," said James V. Cassella, PhD, Senior Vice President, Research and Development of Alexza. "The ability to provide a proven drug mechanism of action, coupled with rapid pharmacokinetics and patient self-administration, makes Staccato loxapine a potentially important new drug candidate for treating agitation in schizophrenic patients."

Clinical Trial Design

The Phase IIa clinical trial was designed as a multi-center, randomized, double-blind, placebo-controlled study of 120 patients in an in-patient clinical setting. In the trial, two doses of AZ-004 (Staccato loxapine in 5 and 10
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-004 (Staccato Loxapine) Clinical Data at the Annual NCDEU Meeting
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/23/2015)... MYERS, Fla. , Jan. 23, 2015  Today the ... of Novartis, Bexsero® for the prevention of serogroup ... 25. Bexsero and Pfizer,s vaccine Trumenba®, which received FDA ... helping prevent this devastating disease. "I ...
(Date:1/23/2015)... Iowa , Jan. 23, 2015  The Partnership to Fight Chronic ... health care leaders and a new study analyzing the ... The PFCD is a nationwide coalition working to educate policy makers ... released at the Capitol was focused on how the ...
(Date:1/23/2015)... 23, 2015 More than a third of reproductive-aged women ... with private insurance, filled a prescription for an opioid pain ... this week,s Morbidity and Mortality Weekly Report (MMWR). ... treat moderate to severe pain.  They are also found in ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... Feb. 17 The United States, fifth hand ... home to Massena, New York this week after ... of Kleinert Kutz and University of Louisville ... UofL hand surgeons performed the Hondusky,s hand transplant ...
... Sanofi Pasteur, the,vaccines division of sanofi-aventis Group (EURONEXT ... is sponsoring a phase II clinical study of a ... causes of,hospital-acquired infection in Europe and North America. , ... the United Kingdom is investigating the,safety and efficacy of ...
Cached Medicine Technology:Fifth U.S. Hand Transplant Patient Heads Home to NY 2Fifth U.S. Hand Transplant Patient Heads Home to NY 3Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 2Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 3Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 4Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 5
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... ... everyone will carry their snacks while on the go. KUBBE is the first and ... hassle free. , ... 17, 2010 -- KUBBE is a trendy plastic utility buckle that allows people to carry ...
... , , ... ... ... ...
... ... ... ... ...
... in the March issue of Radiology , researchers from ... have determined that an imaging exam of the heart using ... much as 91 percent less radiation than standard helical CT ... in recent years, due to its diagnostic accuracy in assessing ...
... ... ... ... ...
... ... ... ... , ...
Cached Medicine News:Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 2Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 3Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 4Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 5Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 6Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 7Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 2Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 3Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 4Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 5Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 6Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 7Health News:New cardiac CT technology drastically reduces patient radiation exposure 2Health News:E-Cigarette Maker Green Smoke Tells FDA to Back Off! 2Health News:E-Cigarette Maker Green Smoke Tells FDA to Back Off! 3Health News:E-Cigarette Maker Green Smoke Tells FDA to Back Off! 4Health News:Healthcare Realty Trust Announces Fourth Quarter Results 2Health News:Healthcare Realty Trust Announces Fourth Quarter Results 3Health News:Healthcare Realty Trust Announces Fourth Quarter Results 4Health News:Healthcare Realty Trust Announces Fourth Quarter Results 5Health News:Healthcare Realty Trust Announces Fourth Quarter Results 6Health News:Healthcare Realty Trust Announces Fourth Quarter Results 7Health News:Healthcare Realty Trust Announces Fourth Quarter Results 8Health News:Healthcare Realty Trust Announces Fourth Quarter Results 9Health News:Healthcare Realty Trust Announces Fourth Quarter Results 10Health News:Healthcare Realty Trust Announces Fourth Quarter Results 11Health News:Healthcare Realty Trust Announces Fourth Quarter Results 12Health News:Healthcare Realty Trust Announces Fourth Quarter Results 13Health News:Healthcare Realty Trust Announces Fourth Quarter Results 14Health News:Healthcare Realty Trust Announces Fourth Quarter Results 15
... catheter design was created to be ... still providing high suctioning efficiency. Our ... or 10 Fr) feature depth markings ... Our complete catheter line is available ...
Suction catheter with thumb valve, two eyes, whistle tip...
Tracheal Suction Latex Rubber Catheters - Thumb Control Valve...
Rubber bronchial coude catheter, X-ray opaque, one eye, whistle tip....
Medicine Products: